|
gptkbp:instanceOf
|
gptkb:drug
PDE5 inhibitor
|
|
gptkbp:approvalYear
|
2005
|
|
gptkbp:ATCCode
|
G04BE10
|
|
gptkbp:CASNumber
|
268203-93-6
|
|
gptkbp:category
|
erectile dysfunction drug
|
|
gptkbp:contraindication
|
nitrate medications
|
|
gptkbp:countryOfOperation
|
gptkb:South_Korea
|
|
gptkbp:developedBy
|
gptkb:Dong-A_Pharmaceutical
|
|
gptkbp:eliminationHalfLife
|
7.3-12.1 hours
|
|
gptkbp:hasMolecularFormula
|
C25H36N6O4S
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Udenafil
|
|
gptkbp:IUPACName
|
3-(1-methyl-7-oxo-3-propyl-4,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-N-[2-(1-methylpyrrolidin-2-yl)ethyl]-4-propoxybenzenesulfonamide
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
gptkb:Zydena
|
|
gptkbp:mechanismOfAction
|
phosphodiesterase type 5 inhibition
|
|
gptkbp:PubChem_CID
|
9910491
|
|
gptkbp:relatedTo
|
gptkb:vardenafil
gptkb:avanafil
gptkb:sildenafil
gptkb:tadalafil
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
headache
nasal congestion
dyspepsia
flushing
|
|
gptkbp:usedFor
|
erectile dysfunction
|
|
gptkbp:bfsParent
|
gptkb:Zydus_Cadila
|
|
gptkbp:bfsLayer
|
6
|